Tetsuya Mishima has served as the CEO of Epigeneron since March, 2021. Prior to joining Epigeneron, he was the CEO of Anaeropharma Science, a clinical stage biotech company. Prior to Anaeropharma, He was a partner of Watervein Partners, a venture capital firm, which he co-founded in 2002. Prior to founding Watervein, he was involved in the M&A advisory business at Bank of America Investment Banking, and in the pharmaceutical business at AGC. Throughout his career, he has extensive experiences in pharmaceutical development, alliance management, fundraising, and venture investment. He received a B.S. and an M.S. in Polymer Science at Tokyo Institute of Technology.
Hodaka Fujii, M.D., Ph.D.
Founder and Director, CSO
Dr. Hodaka Fujii is a Founder and the CSO of Epigeneron. He is also a Professor at Hirosaki University Graduate School of Medicine and School of Medicine. Prior to this position, he was an Associate Professor at Osaka University and an Assistant Professor at New York University School of Medicine, and a Scientific Member of Basel Institute for Immunology. During his professional career, Dr. Fujii has focused on immunology, molecular biology and epigenetics / chromatin. He received an M.D. and Ph.D. from the University of Tokyo School of Medicine and Graduate School of Medicine, respectively.
Director, Business Development
Mr. Masayuki Furutsuka has focused on alliance, collaboration and partnering through strategic and transformational transactions in pharmaceutical industry totaling over $5 Billion in value. Prior to joining Epigeneron in 2019, Mr. Furutsuka was Business Development and Partnering Head of Japan Vaccine business unit at Takeda. Prior to Takeda, he served as a head of Japan group, Corporate business development / Global business Development at Eisai where he led the corporate partnering initiatives. From 2000 to 2007, he was in research division and business development at Astellas. He holds an M.S. in the agriculture science at Kobe University.
Atsushi Usami, Ph.D.
Dr. Atsushi Usami is a Partner and one of the Board Directors of The University of Tokyo Edge Capital Partners Co. Ltd. (UTEC). Since joining in 2013, he has focused on seed / early-stage life science investments. He currently serves on the board of Epigeneron Inc. Before joining UTEC, he worked as a strategy consultant at Mitsubishi Research Institute (MRI). He received a Ph.D. in pharmaceutical sciences from the University of Tokyo and is a pharmacist.
Atsushi Shimada has more than 20 years experiences in business development and licensing in the pharmaceutical industry with diverse experiences in intellectual property work as a Patent Attorney at Takeda and Bayer Pharmaceuticals. As a business development executive, he has lead triple-digit-value deals locally and globally managing multi-discipline team, and also have rich experiences working with biotech globally.